HC Wainwright Downgrades Savara (NASDAQ:SVRA) to Neutral

Savara (NASDAQ:SVRA - Get Free Report) was downgraded by investment analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a report released on Thursday, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their prior target price of $6.00. HC Wainwright's price target would suggest a potential downside of 12.66% from the stock's previous close. HC Wainwright also issued estimates for Savara's FY2029 earnings at $0.08 EPS.

Several other equities analysts also recently commented on SVRA. Evercore ISI lowered their price objective on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday. Wells Fargo & Company lowered their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Guggenheim reaffirmed a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.17.

Savara Price Performance

Shares of Savara stock traded up $0.05 during trading hours on Thursday, hitting $2.29. The company's stock had a trading volume of 2,115,463 shares, compared to its average volume of 1,427,313. The business has a 50 day moving average price of $2.92 and a two-hundred day moving average price of $2.95. Savara has a 12-month low of $1.89 and a 12-month high of $5.11. The company has a market cap of $395.80 million, a PE ratio of -5.33 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). Analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several large investors have recently made changes to their positions in the company. Altium Capital Management LLC increased its holdings in shares of Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock worth $4,848,000 after purchasing an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after acquiring an additional 4,732 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Savara by 13.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock worth $135,000 after acquiring an additional 5,236 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Savara by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after acquiring an additional 5,450 shares during the last quarter. Finally, Barclays PLC increased its stake in Savara by 2.5% during the fourth quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after acquiring an additional 5,700 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.